Yale University

Adenovir Pharma Ab

Eirium Ab

Mikael Elofsson

Craig M Crews

Ute Splittgerber

Kyung Bo Kim

Ny Sin

Niklas Arnberg

Christopher Öberg

Göran Wadell

Marten Strand

Emma Andersson

Rémi Caraballo

Ya-Fang Mei

Karin Edlund

Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.

Multivalent sialic acid derivatives

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.

Antiviral compounds

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.

Enzyme inhibition

Growing community of inventors

Umeå, Sweden

Mikael Elofsson